p53 antibody [N1], N-term
GTX100629
ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetTP53
Overview
- SupplierGeneTex
- Product Namep53 antibody [N1], N-term
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID7157
- Target nameTP53
- Target descriptiontumor protein p53
- Target synonymsBCC7, BMFS5, LFS1, P53, TRP53, cellular tumor antigen p53, antigen NY-CO-13, mutant tumor protein 53, phosphoprotein p53, transformation-related protein 53, tumor protein 53, tumor supressor p53
- HostRabbit
- IsotypeIgG
- Protein IDP04637
- Protein NameCellular tumor antigen p53
- Scientific DescriptionThis gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where its believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Aljohani AA, Alqarni YS, Alrashidi MN, et al. The Anti-Rheumatic Drug, Leflunomide, Induces Nephrotoxicity in Mice via Upregulation of TGFβ-Mediated p53/Smad2/3 Signaling. Toxics. 2022,10(5). doi: 10.3390/toxics10050274Read this paper
- Doddapaneni R, Tao W, Naranjo A, et al. Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland. Oncotarget. 2019,10(4):480-493. doi: 10.18632/oncotarget.26558Read this paper
- Mlcochova P, Caswell SJ, Taylor IA, et al. DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages. EMBO J. 2018,37(1):50-62. doi: 10.15252/embj.201796880Read this paper
- Abdi J, Mutis T, Garssen J, et al. Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells. Blood Cancer J. 2013,3(5):e119. doi: 10.1038/bcj.2013.17Read this paper
- Chen YJ, Chen HP, Cheng YJ, et al. The synthetic flavonoid WYC02-9 inhibits colorectal cancer cell growth through ROS-mediated activation of MAPK14 pathway. Life Sci. 2013,92(22):1081-92. doi: 10.1016/j.lfs.2013.04.007Read this paper






